ACSL6 Inhibitors

Triacsin C is known to inhibit long-chain acyl-CoA synthetases (ACSLs). Since ACSL6 is a member of this enzyme family, Triacsin C can inhibit its activity by preventing the conversion of free long-chain fatty acids into fatty acyl-CoA esters, thus directly affecting the enzymatic function of ACSL6.

TOFA is an allosteric inhibitor of acetyl-CoA carboxylase, which, similarly to Soraphen A, can lower malonyl-CoA levels and indirectly inhibit ACSL6 by limiting its substrate pool for fatty acid activation.

Cerulenin is a fatty acid synthase inhibitor, which can lead to decreased synthesis of fatty acids. This decrease may reduce the availability of fatty acids for ACSL6 to act upon, thereby functionally inhibiting the protein.

C75 is a synthetic compound that inhibits fatty acid synthase and stimulates fatty acid oxidation. By inhibiting fatty acid synthesis, C75 can limit the availability of substrates for ACSL6, leading to its functional inhibition.

Perhexiline inhibits carnitine palmitoyltransferase-1 (CPT-1), which may increase intracellular fatty acid levels. The elevation of fatty acids could feedback inhibit ACSL6 by product inhibition, where the accumulating fatty acyl-CoAs inhibit their own synthesis.

Etomoxir inhibits carnitine palmitoyltransferase-1 (CPT-1), leading to increased fatty acyl-CoA levels inside cells. The increased levels of fatty acyl-CoAs can serve as feedback inhibitors for ACSL6, thus inhibiting its activity.

Ranolazine is known to inhibit fatty acid oxidation by partially inhibiting fatty acid β-oxidation enzymes. This inhibition can increase intracellular levels of long-chain fatty acyl-CoAs, potentially leading to feedback inhibition of ACSL6.

Oxfenicine inhibits carnitine palmitoyltransferase-1 (CPT-1), which can lead to an increase in intracellular long-chain fatty acyl-CoA levels. Elevated levels of these fatty acids can feedback inhibit ACSL6, thereby functionally inhibiting the protein.